Want to Donate?
You are taking a valuable step in supporting those affected by this debilitating condition. Your contribution today will help bring hope for our future generations.
Based in the USA
CurePSP is the leading nonprofit organization dedicated to the awareness, care and cure for three neurodegenerative diseases: progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and multiple system atrophy (MSA). As a catalyst for new treatments and a cure, it establishes important partnerships and funds critical research. Through their advocacy and support efforts, it enhances education, care delivery and quality of life for people living with PSP, CBD and MSA and their families. Science, community and hope are at the heart of CurePSP’s mission and all of our services.
CurePSP is a registered 501(c)(3) charity within the United States (Federal Employer ID Number: 52-1704978). Their work is possible thanks to the generosity and support of those in our community and beyond.
The Rossy Progressive Supranuclear Palsy (PSP) Centre - is a highly specialized team of healthcare professionals and scientists conducting intensive clinical care and research to advance knowledge of PSP and related disorders. The Rossy PSP Centre, is a research division of the University Health Network. UHN encompasses the Toronto General and Toronto Western hospitals, the Princess Margaret Cancer Centre, Toronto Rehabilitation Institute, and The Michener Institute of Education at UHN. The scope of research and complexity of cases at UHN has made it a national and international source for discovery, education, and patient care. It has the largest hospital-based research program in Canada.
The Rossy PSP Centre has been established to advance clinical and basic research in Progressive Supranuclear Palsy and related neurodegenerative diseases known as “tauopathies”. The extent of the clinical data collected permits in-depth assessments of patients to serve as the basis of future clinical and basic research. Longer-term follow-up assessments combined with research studies involving analysis of a variety of biological samples, including blood, saliva, skin, and cerebrospinal fluid, are designed to develop more reliable methods of making a diagnosis at the earliest stages (“biomarkers”) and establish a better understanding of the underlying disease mechanisms (“pathogenesis”). It is hoped that advances from this work will bring us closer to the sorely needed treatments that will slow and eventually prevent the progression of the disease and the careful clinical documentation will allow fast-tracking of well-characterized patients into clinical trials of these future therapies.”